Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials)

• Published in: The American journal of cardiology Vol. 117; no. 2; pp. 186 - 191
• Main Authors: Ng, Vivian G., MD, Baumbach, Andreas, MD, Grinfeld, Liliana, MD, Lincoff, A. Michael, MD, Mehran, Roxana, MD, Stone, Gregg W., MD, Lansky, Alexandra J., MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15-01-2016; Elsevier Limited
• Subjects: Acute coronary syndromes; Aged; Antithrombins - administration & dosage; Antithrombins - adverse effects; Argentina - epidemiology; Blood transfusions; Cardiology; Cardiovascular; Confidence intervals; Coronary vessels; Diabetes; Electrocardiography; Female; Follow-Up Studies; Gender; Heart attacks; Heart surgery; Hemorrhage - chemically induced; Hemorrhage - mortality; Hirudins - administration & dosage; Hirudins - adverse effects; Humans; Hypertension; Ischemia; Male; Medical imaging; Middle Aged; Mortality; Multivariate analysis; Myocardial Infarction - mortality; Myocardial Infarction - therapy; Peptide Fragments - administration & dosage; Peptide Fragments - adverse effects; Percutaneous Coronary Intervention - methods; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Risk Factors; Survival Rate - trends; Time Factors; United Kingdom - epidemiology; United States - epidemiology; Variables; Veins & arteries; Women
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2015.10.029

Women have higher bleeding complication and mortality rates after percutaneous coronary interventions (PCI). The contribution of female gender to bleeding and mortality is poorly understood. We evaluated the effect of gender and bleeding on outcomes of patients treated with bivalirudin during PCI by performing a patient-level pooled analysis of 3 randomized controlled trials (the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events, Acute Catheterization and Urgent Intervention Triage strategY, and Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor (GPI) treatment in patients undergoing PCI. Of 14,784 patients, 7,413 patients received bivalirudin (1,870 women) and 7,371 patients received heparin + GPI (1,910 women). Women had significantly higher 30-day non–coronary artery bypass grafting (CABG)-related major bleeding rates (7.6% vs 3.8%, p <0.0001). After multivariate adjustment, female gender increased the hazard of major bleeding by 80% (hazard ratio 1.80, 95% confidence interval 1.52 to 2.11, p <0.001). Furthermore, women had a higher 1-year mortality rate (3.7% vs 2.7%, p = 0.002) than men; 30-day major bleeding was the strongest independent predictor of 1-year mortality in women (hazard ratio 2.48, 95% confidence interval 1.57 to 3.91, p = 0.001). Bivalirudin therapy in women reduced 30-day non–CABG-related major bleeding (5.6% vs 9.7%, p <0.0001) and 1-year mortality (2.9% vs 4.4%, p = 0.02) compared to standard therapy. In conclusion, in this cohort of patients treated for acute coronary syndrome and ST-segment elevation myocardial infarction, women have a near 2-fold increase in bleeding complications compared to men after PCI. Bleeding complications rather than gender is the strongest independent predictor of 1-year mortality in patients undergoing PCI. Furthermore, we observed a more pronounced clinical benefit in women treated with bivalirudin including a 44% reduction in major bleeding and a significant reduction in mortality rates at 1 year.